- This topic has 0 replies, 1 voice, and was last updated 3 months ago by
.
Viewing 0 reply threads
-
Posts
-
-
NICE is the government agency that recommends which drugs should be provided to National Health Service patients in England and Wales. It’s just said no to Zeposia (ozanimod), claiming it’s not as cost-effective as Avonex (inteferon beta1-a) to treat MS.
Have you considered switching from Avonex to Zeposia? Should cost-effectiveness ever be a factor in the ability to have a medication prescribed?
-
Viewing 0 reply threads
- You must be logged in to reply to this topic.
